Bausch's OraPharma expands into Canada, Puerto Rico

Executive Summary

• Bausch Health’s subsidiary, OraPharma, has commercially expanded its operations into Canada and Puerto Rico.
• The expansion focuses on distributing Arestin, the company's flagship FDA-approved locally applied antibiotic for periodontal disease management.
• The move aims to address unmet needs in periodontal care, leveraging partnerships with local distributors and dental professionals in these new markets.

Key Details

• Expansion Markets: Commercial expansion into Canada and Puerto Rico.
• Strategic Partnerships: Strengthening partnerships with local distributors and dental professionals in the new territories.
• Flagship Product: Arestin (minocycline HCl) Microspheres, 1 mg.
• Product Indication: Arestin is the only FDA-approved locally applied antibiotic used as an adjunct to scaling and root planing (SRP) for pocket depth reduction in adult periodontitis.
• Market Context:
  • Globally, over one billion people are affected by periodontal disease (Global Burden of Disease Study, 2021).
  • In Canada, the Canadian Dental Association estimates seven in ten Canadians will develop gum disease in their lifetime.
  • In Puerto Rico, 44.5% of older adults live with moderate to severe periodontal disease.
• Company Background: OraPharma has over two decades of clinical experience with Arestin.

Notable Quotes

• "OraPharma remains committed to addressing periodontal disease, a condition that affects more than 1 billion globally," said Tom Stern, vice-president and general manager, OraPharma, Bausch Health. "By expanding access to Arestin in Canada and Puerto Rico, we aim to help address the gaps in care and provide dental professionals with a treatment option to support improved oral health for their adult periodontitis patients."